research Androgenic Effects on Ventricular Repolarization
ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Prevalence and associated factors of skin diseases in aged nursing home residents: a multicentre prevalence study
Nearly all elderly nursing home residents had a skin disease, with dry skin being the most common.
research Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment
Scalp cooling significantly reduces hair loss in chemotherapy patients.
research Tofacitinib for the treatment of alopecia areata in preadolescent children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
research Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial
PRP treatment improves hair density and thickness for alopecia, but needs more research.
research Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia
Dutasteride safely promotes hair growth and reduces hair loss, with mild side effects.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women
Both Platelet-Rich Plasma and Minoxidil foam increase hair count in women with hair loss, but Minoxidil is more effective. However, women were more satisfied with Platelet-Rich Plasma treatment.
research Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.
research Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
research Efficacy and safety of minoxidil 3% lotion for beard enhancement: A randomized, double‐masked, placebo‐controlled study
Minoxidil 3% lotion is effective and safe for increasing beard hair count.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial
Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.
research Post-Finasteride Syndrome: About 2 Cases and Review of the Literature
research Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
research 491 Efficacy of oral tofacitinib in the treatment of lichen planopilaris
Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
research 0914 Association Between Obstructive Sleep Apnea, Nightmare Disorder and Incident Herpes Zoster
People with obstructive sleep apnea are more likely to get herpes zoster, but nightmares don't affect the risk.
research Efficacy of tofacitinib in pediatric alopecia universalis
Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
research All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity
All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
research Efficacy and Safety of a Proprietary Free Fatty Acid Rich Saw Palmetto Extract (USPlus<sup>®</sup> PRO) for Lower Urinary Tract Symptoms in Males: A Randomized, Double-Blind, Placebo-Controlled Trial
USPlus PRO saw palmetto extract improves urinary symptoms and is safe for men.
research Efficacy and Safety of a Drinkable Nutraceutical in Premenopausal Women with Telogen Effluvium: A 6-Month, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study
The drinkable supplement increased hair growth and was safe for women with hair loss.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research A 6-Month, Prospective, Multi-arm Study for the Efficacy of Standardized Nutraceuticals to Improve Hair Fiber Thickness and Strength
Nutrafol® nutraceuticals improve hair thickness and strength.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.